CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
37.77
-0.01 (-0.03%)
At close: Apr 17, 2025, 4:00 PM
37.66
-0.11 (-0.29%)
Pre-market: Apr 21, 2025, 4:22 AM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 74.35, with a low estimate of 32 and a high estimate of 120. The average target predicts an increase of 96.85% from the current stock price of 37.77.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 | 7 | 6 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 9 | 9 | 9 | 9 | 9 | 8 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 18 | 19 | 21 | 21 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +122.40% | Apr 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 19, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $89 → $82 | Strong Buy | Maintains | $89 → $82 | +117.10% | Feb 18, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $30 → $32 | Sell | Maintains | $30 → $32 | -15.28% | Feb 14, 2025 |
| Evercore ISI Group | Evercore ISI Group | Hold → Buy Upgrades $60 → $99 | Hold → Buy | Upgrades | $60 → $99 | +162.11% | Feb 14, 2025 |
Financial Forecast
Revenue This Year
56.47M
from 37.31M
Increased by 51.35%
Revenue Next Year
215.82M
from 56.47M
Increased by 282.16%
EPS This Year
-5.02
from -4.34
EPS Next Year
-4.19
from -5.02
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 164.9M | 1.6B | 2.4B | ||
| Avg | 56.5M | 215.8M | 486.2M | ||
| Low | n/a | n/a | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 341.8% | 2,651.8% | 1,002.8% | ||
| Avg | 51.3% | 282.2% | 125.3% | ||
| Low | - | - | -59.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.06 | 4.15 | 5.79 | ||
| Avg | -5.02 | -4.19 | -2.64 | ||
| Low | -6.80 | -7.54 | -7.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.